FAQs

You may be considering enrolling in the ongoing global atypical hemolytic uremic syndrome (aHUS) registry. Here are some frequently asked questions and answers about the registry to help you learn more about it. What is the global aHUS registry? The global aHUS registry is an observational study (NCT01522183)…

Soliris (eculizumab) is a medication developed by Alexion to treat atypical hemolytic uremic syndrome (aHUS). Here are some frequently asked question and answers about Soliris: How does Soliris work? In aHUS, a part of the immune system called the complement system becomes active when…

Ultomiris (ravulizumab-cwvz) is a treatment for atypical hemolytic uremic syndrome (aHUS) that was developed by Alexion. The therapy is designed to treat people with low levels of circulating red blood cells. Here are some frequently asked question and answers about Ultomiris: How does it work? In…

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the formation of blood clots in the small blood vessels of the kidneys. The kidneys filter waste out of the blood, but blood clots may interfere with blood flow and prevent the kidneys from doing…

Atypical hemolytic uremic syndrome (aHUS) is a rare genetic disease associated with symptoms such as hemolytic anemia (loss of red blood cells) and thrombocytopenia (low platelet count). In severe cases, the disease can lead to chronic kidney disease and…

Information about rare diseases such as atypical hemolytic uremic syndrome (aHUS) can be difficult to find, complicating the situation for both patients and caregivers. Here are answers to some of the more frequently asked questions about aHUS to serve as a ready reference. We also include suggestions for other…